Clinical trial
A Study To Evaluate PRX-00023 In Patients With Generalized Anxiety Disorder…
NCT00248183 · Epix Pharmaceuticals, Inc., Industry · Completed
Key facts
| NCT number | NCT00248183 |
|---|---|
| Title | A Study To Evaluate PRX-00023 In Patients With Generalized Anxiety Disorder (GAD) |
| Official title | A Randomized, Double Blind, Placebo Controlled, Multicenter Study To Evaluate The Efficacy, Safety, And Tolerability Of PRX-00023 In Patients With Generalized Anxiety Disorder (GAD) |
| Lead sponsor | Epix Pharmaceuticals, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Anxiety Disorders |
| Intervention type | Drug |
| Interventions | PRX-00023 |
| Enrollment | 310 |
| Start date | Aug 1, 2005 |
| Completion | Jun 1, 2006 |
| First posted | Nov 3, 2005 |
| Last update posted | Apr 3, 2008 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: